Advertisement

Clinical Rheumatology

, Volume 37, Issue 10, pp 2741–2749 | Cite as

Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic

  • Michele Maria LuchettiEmail author
  • Devis Benfaremo
  • Anna Campanati
  • Elisa Molinelli
  • Monia Ciferri
  • Serena Cataldi
  • William Capeci
  • Marco Di Carlo
  • Anna Maria Offidani
  • Fausto Salaffi
  • Armando Gabrielli
Original Article

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune arthritis, occurring in patients with psoriasis (Pso), that may affect the whole musculoskeletal system but also nails, eye, and gastrointestinal tract. Dermatologists and rheumatologists usually manage Pso and PsA separately, but early diagnosis and integrated management could achieve better outcomes of both skin and musculoskeletal manifestations, thus improving the health-related quality of life (HRQoL) of patients. In this work, we have described a model of integrated dermo-rheumatologic approach for the early diagnosis of PsA and to present the outcomes of the multidisciplinary management of PsA patients after 48 weeks of follow-up. Pso patients complaining musculoskeletal symptoms were enrolled in a DErmo-Rheumatologic Clinic (DERC) in order to screen, classify, and treat patients with PsA, employing an operative working procedure and a specific flowchart. The integrated dermatologic and rheumatologic management of PsA patients allowed a prompt establishment of the diagnosis and the best therapeutic approach in these patients, with a significant improvement of skin and articular diseases and, eventually, a consistent amelioration of HRQoL. Dermatologists and rheumatologists usually manage the “psoriatic disease” in separated outpatient clinics. In our study, we have demonstrated that a combined DERC, by means of a tight cooperation between the dermatologist and the rheumatologist, which use a specific working procedure and treatment flowchart, may achieve the optimal clinical management of these patients, with a consistent clinical remission of the disease and a significant amelioration of the HRQoL.

Keywords

Dermo-rheumatologic clinic (DERC) Health related quality of life psoriatic disease 

Notes

Acknowledgments

We are grateful to all the patients included in the DERC that gave their consent to use the data for the scope of this report.

Authors’ contribution

LMM and BD designed the work, performed the clinical examinations, analyzed the data, and wrote the paper, giving equal contribution to the work as first authors; CA designed the work and performed the clinical examinations; ME, CW, CM, CS, DCM performed the clinical examinations; OAM, SF, and GA conceived the work, analyzed the data, and wrote the paper, giving equal contribution as senior authors.

Compliance with ethical standards

Written informed consent was obtained from all the patients.

Disclosures

None.

Ethical approval and consent to participate

This work was conducted in accordance with the ethical principles of the Helsinki Declaration of 1975 and revised in 1983, and in accordance with the ethical standards of the institutional responsible committee on human experimentation.

Supplementary material

10067_2018_4238_MOESM1_ESM.docx (23 kb)
ESM 1 (DOCX 23 kb)

References

  1. 1.
    Ritchlin C, Colbert R, Gladman D (2017) Psoriatic arthritis. N Engl J Med 376:957–970.  https://doi.org/10.1056/nejmra1505557 CrossRefPubMedGoogle Scholar
  2. 2.
    McHugh N (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42:778–783.  https://doi.org/10.1093/rheumatology/keg217 CrossRefPubMedGoogle Scholar
  3. 3.
    Coates L, Conaghan P, Emery P et al (2012) Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 64:3150–3155.  https://doi.org/10.1002/art.34536 CrossRefPubMedGoogle Scholar
  4. 4.
    Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J (2009) The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783.  https://doi.org/10.1136/ard.2009.108233 CrossRefPubMedGoogle Scholar
  5. 5.
    Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sorensen IJ, Valle-Onate R, Weber U, Wei J, Sieper J (2010) The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31.  https://doi.org/10.1136/ard.2010.133645 CrossRefPubMedGoogle Scholar
  6. 6.
    Gossec L, Smolen J, Ramiro S et al (2015) European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499–510.  https://doi.org/10.1136/annrheumdis-2015-208337 CrossRefPubMedGoogle Scholar
  7. 7.
    Coates L, Kavanaugh A, Mease P et al (2016) Group for Research and Assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum 68:1060–1071.  https://doi.org/10.1002/art.39573 CrossRefGoogle Scholar
  8. 8.
    Cañete J, Daudén E, Queiro R et al (2014) Recommendations for the coordinated Management of Psoriatic Arthritis by rheumatologists and dermatologists: a Delphi study. Actas Dermo-Sifiliográficas (English Edition) 105:216–232.  https://doi.org/10.1016/j.adengl.2013.07.003 CrossRefGoogle Scholar
  9. 9.
    Gratacos-Masmitja J, Luelmo-Aguilar J, Zarco-Montejo P, Botella-Estrada R, Carrizosa-Esquivel AM, Garcia-Vivar ML, Perez-Barrio S, Roman-Ivorra JA, Ruiz-Montesino MD, Lopez-Estebaranz JL (2016) Points to consider in the Foundation of Multidisciplinary Units for psoriatic arthritis: a Delphi study and a systematic review of the literature. Adv Ther 33:2150–2159.  https://doi.org/10.1007/s12325-016-0429-z CrossRefPubMedGoogle Scholar
  10. 10.
    Gordon K, Ruderman E (2006) The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol 54:S85–S91.  https://doi.org/10.1016/j.jaad.2005.10.052 CrossRefPubMedGoogle Scholar
  11. 11.
    Salaffi F, Di Carlo M, Luchetti MM et al (2018) A validation study of the simple psoriatic arthritis screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. Clin Exp Rheumatol 36:127–135PubMedGoogle Scholar
  12. 12.
    Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, Costanzo A, Conti A, Dapavo P, de Simone C, Foti C, Naldi L, Offidani A, Parodi A, Piaserico S, Prignano F, Rongioletti F, Stingeni L, Talamonti M, Girolomoni G (2017) Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 31:774–790.  https://doi.org/10.1111/jdv.14114 CrossRefPubMedGoogle Scholar
  13. 13.
    Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25.  https://doi.org/10.1186/1477-7525-7-25 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Antoni C (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150–1157.  https://doi.org/10.1136/ard.2004.032268 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Mease P, Kivitz A, Burch F et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264–2272.  https://doi.org/10.1002/art.20335 CrossRefPubMedGoogle Scholar
  16. 16.
    Wong K, Gladman D, Husted J et al (1997) Mortality studies in psoriatic arthritis. Results from a single outpatient clinic I Causes and risk of death. Arthritis Rheum 40:1868–1872.  https://doi.org/10.1002/art.1780401021 CrossRefPubMedGoogle Scholar
  17. 17.
    Walsch J, Callis Duffin K, Krueger G, Clegg D (2013) Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol 40:287–293.  https://doi.org/10.3899/jrheum.120836 CrossRefGoogle Scholar
  18. 18.
    Haroon M, Kirby B, FitzGerald O (2012) High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 72:736–740.  https://doi.org/10.1136/annrheumdis-2012-201706 CrossRefPubMedGoogle Scholar
  19. 19.
    Kingsley G, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 51:1368–1377.  https://doi.org/10.1093/rheumatology/kes001 CrossRefPubMedGoogle Scholar
  20. 20.
    Mease P, Ory P, Sharp J et al (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 68:702–709.  https://doi.org/10.1136/ard.2008.092767 CrossRefPubMedGoogle Scholar
  21. 21.
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986.  https://doi.org/10.1002/art.24403 CrossRefPubMedGoogle Scholar
  22. 22.
    Mease P, Fleischmann R, Deodhar A et al (2013) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48–55.  https://doi.org/10.1136/annrheumdis-2013-203696 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    McInnes I, Kavanaugh A, Gottlieb A et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780–789.  https://doi.org/10.1016/s0140-6736(13)60594-2 CrossRefPubMedGoogle Scholar
  24. 24.
    Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329–1339.  https://doi.org/10.1056/nejmoa1412679 CrossRefPubMedGoogle Scholar
  25. 25.
    Mease P, van der Heijde D, Ritchlin C, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD, SPIRIT-P1 Study Group (2016) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79–87.  https://doi.org/10.1136/annrheumdis-2016-209709 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kavanaugh A, Mease P, Gomez-Reino J et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026.  https://doi.org/10.1136/annrheumdis-2013-205056 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Luchetti M, Benfaremo D, Gabrielli A (2018) Biologics in inflammatory and Immunomediated arthritis. Curr Pharm Biotechnol 18:989–1007.  https://doi.org/10.2174/1389201019666171226151852 CrossRefGoogle Scholar
  28. 28.
    Luchetti M, Benfaremo D, Ciccia F et al (2017) Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study. World J Gastroenterol 23:7139–7149.  https://doi.org/10.3748/wjg.v23.i39.7139 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Qureshi A, Husni M, Mody E (2005) Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg 24:46–51.  https://doi.org/10.1016/j.sder.2005.01.006 CrossRefPubMedGoogle Scholar
  30. 30.
    Cobo-Ibáñez T, Villaverde V, Seoane-Mato D, Muñoz-Fernández S, Guerra M, del Campo PD, Cañete JD (2015) Multidisciplinary dermatology–rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol Int 36:221–229.  https://doi.org/10.1007/s00296-015-3377-z CrossRefPubMedGoogle Scholar
  31. 31.
    Velez N, Wei-Passanese E, Husni M et al (2011) Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res 304:7–13.  https://doi.org/10.1007/s00403-011-1172-6 CrossRefGoogle Scholar
  32. 32.
    Pérez-Barrio S, Galindez E, Alzaga J (2014) Psoriasis and psoriatic arthropathy multidisciplinary clinic at Basurto University hospital: 2 years of experience. J Am Acad Dermatol 70:AB180.  https://doi.org/10.1016/j.jaad.2014.01.746 CrossRefGoogle Scholar
  33. 33.
    Foulkes A, Chinoy H, Warren RB (2012) High degree of patient satisfaction and exceptional feedback in a specialist combined dermatology and rheumatology clinic. Br J Dermatol 167:38Google Scholar
  34. 34.
    Di Carlo M, Luchetti M, Benfaremo D et al (2017) The DETection of arthritis in inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis. Clin Rheumatol 37:1037–1044.  https://doi.org/10.1007/s10067-017-3937-6 CrossRefPubMedGoogle Scholar
  35. 35.
    Luchetti M, Ciccia F, Avellini C et al (2018) Sclerostin and Antisclerostin antibody serum levels predict the presence of axial Spondyloarthritis in patients with inflammatory bowel disease. J Rheumatol 45:630–637.  https://doi.org/10.3899/jrheum.170833 CrossRefPubMedGoogle Scholar
  36. 36.
    Gladman D (1994) Natural history of psoriatic arthritis. Baillière's Clin Rheumatol 8:379–394.  https://doi.org/10.1016/s0950-3579(94)80024-3 CrossRefGoogle Scholar
  37. 37.
    Radtke M, Reich K, Blome C, Rustenbach S, Augustin M (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23:683–691.  https://doi.org/10.1111/j.1468-3083.2009.03159.x CrossRefPubMedGoogle Scholar
  38. 38.
    Kane D (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42:1460–1468.  https://doi.org/10.1093/rheumatology/keg384 CrossRefPubMedGoogle Scholar
  39. 39.
    Coates L, Aslam T, Al Balushi F et al (2013) Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 168:802–807.  https://doi.org/10.1111/bjd.12190 CrossRefPubMedGoogle Scholar
  40. 40.
    Karreman M, Weel A, van der Ven M et al (2016) Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. Rheumatology kew410.  https://doi.org/10.1093/rheumatology/kew410
  41. 41.
    Coates L, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes I, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh N, BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR (2013) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology 52:1754–1757.  https://doi.org/10.1093/rheumatology/ket187 CrossRefPubMedGoogle Scholar
  42. 42.
    Samarasekera E, Sawyer L, Parnham J, Smith C (2012) Assessment and management of psoriasis: summary of NICE guidance. BMJ 345:e6712–e6712.  https://doi.org/10.1136/bmj.e6712 CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Michele Maria Luchetti
    • 1
    Email author
  • Devis Benfaremo
    • 1
  • Anna Campanati
    • 2
    • 3
  • Elisa Molinelli
    • 2
    • 3
  • Monia Ciferri
    • 1
  • Serena Cataldi
    • 1
  • William Capeci
    • 1
  • Marco Di Carlo
    • 4
  • Anna Maria Offidani
    • 2
    • 3
  • Fausto Salaffi
    • 4
  • Armando Gabrielli
    • 1
  1. 1.Clinica Medica, Dipartimento Scienze Cliniche e MolecolariUniversità Politecnica delle MarcheAnconaItaly
  2. 2.Clinica DermatologicaAzienda Ospedaliero-Universitaria “Umberto I-G.M. Lancisi-G. Salesi”AnconaItaly
  3. 3.Dipartimento Scienze Cliniche e MolecolariUniversità Politecnica delle MarcheAnconaItaly
  4. 4.Clinica Reumatologica, Dipartimento Scienze Cliniche e MolecolariUniversità Politecnica delle Marche and Ospedale “Carlo Urbani”JesiItaly

Personalised recommendations